Výsledky vyhledávání - "Lukas Häselbarth"

Akademický článek

Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment

Autor: Lukas Häselbarth, Sara Gamali, Domenica Saul, Manuela Krumbholz, Romy Böttcher-Loschinski, Martin Böttcher, Deyu Zou, Markus Metzler, Axel Karow, Dimitrios Mougiakakos

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)

Abstract Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors (TKIs), targeting the BCR::ABL1 oncoprotein. Still, resistance to therapy, relapse after treatment discontinuation, and side effects remain significant iss

Externí odkaz: https://doaj.org/article/21d4649d4b6548ffaf9e27d12209e88a

Zobrazit plný text záznamu

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Autor: Lukas, Häselbarth, Axel, Karow, Kristin, Mentz, Martin, Böttcher, Oisin, Roche-Lancaster, Manuela, Krumbholz, Regina, Jitschin, Dimitrios, Mougiakakos, Markus, Metzler

Publikováno v: Cancer Immunology, Immunotherapy. 72:1661-1672

T cell function is central to immune reconstitution and control of residual chronic myeloid leukemia (CML) cells after treatment initiation and is associated with achieving deep molecular response as a prerequisite for treatment-free remission, the u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df2e14101a09e455e48fbac5177b84a
https://doi.org/10.1007/s00262-022-03361-8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání